Approval · Notice of Compliance 22284 · 2019
FOSAPREPITANT: Notice of Compliance 22284
Issued June 14, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22284
- Date
- June 14, 2019
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Update to the product monograph and package insert
- Canadian reference product
- EMEND IV (Merck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOSAPREPITANT | Not yet assigned | — |
Medicinal ingredients
- FOSAPREPITANT DIMEGLUMINE 150 MG per VIAL